Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

November 11, 2021 updated by: Keymed Biosciences Co.Ltd

A Phase I, Multiple Center, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

This is a multi-center, open-label, dose escalation and dose expansion, Phase 1 study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of CM313.

The dose escalation part will determine the MTD of CM313 in subjects with relapsed and/or refractory multiple myeloma (RRMM) or lymphoma based on a modified 3+3 dose escalation design (an accelerated dose titration design followed by traditional 3+3 dose escalation design).

The dose expansion part includes two cohorts. Cohort 1 will evaluate the safety and preliminary anti-tumor activity of CM313 in combination with Dexamethasone in subjects with RRMM. Cohort 2 will evaluate the safety and preliminary anti-tumor activity of CM313 in combination with Rd regimen (Lenalidomide/Dexamethasone) in subjects with RRMM or newly diagnosed MM (NDMM).

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

87

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

  • China
    • Beijing
      • Beijing, Beijing, China
        • Not yet recruiting
        • Peking University Third Hospital
        • Contact:
          • Hongmei Jing, Dr.
      • Beijing, Beijing, China
        • Recruiting
        • Beijing Chao-Yang Hospital
        • Contact:
      • Beijing, Beijing, China
        • Recruiting
        • Beijing Chao-Yang Hospital, Capital Medical University (West Branch)
        • Contact:
          • Zhongxia Huang

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 75 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Key Inclusion Criteria:

  • Dose escalation: subjects with RRMM who have progressed on, or could not tolerate, all available established therapies and subjects with recurrent and refractory lymphoma.
  • Dose expansion_cohort 1: subjects with RRMM who have progressed on, or could not tolerate, all available established therapies.
  • Dose expansion_cohort 2: subjects with RRMM who have progressed on, or could not tolerate, all available established therapies, or subjects with NDMM.
  • For MM: Documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria.
  • For MM: Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 0.5 gram per deciliter (g/dL) or urine M-protein level >=200 milligram per 24 hours (mg/24 h) or light chain multiple myeloma without measurable disease in the serum or the urine: serum immunoglobulin free light chain (FLC) >= 10 mg/dL and abnormal serum immunoglobulin kappa lambda FLC ratio.
  • Eastern Cooperative Oncology Group (ECOG) performance status score <＝2.
  • Women of childbearing potential and male subjects must agree to remain abstinent or use contraceptive methods as defined by the protocol.
  • Side effects of any prior therapy or procedures for any medical condition has recovered to NCI-CTCAE v.5.0 Grade ≤ 1.

Key Exclusion Criteria:

  • Previous treatment with any anti-CD38 therapy.
  • Subjects with concurrent plasma cell leukemia.
  • Received a cumulative dose of corticosteroids equivalent to greater than or equal to ( >=) 140 milligram (mg) of prednisone within the 14-day period before the first dose of study drug (does not include pretreatment medication).
  • Vaccinated with live, attenuated vaccine within 4 weeks prior to the first dose.
  • Received an allogenic stem cell transplant or an autologous stem cell transplant within 3 months before first dose of study drug.
  • Central nervous system (CNS) involvement.
  • The forced expiratory volume in one second (FEV1)<60%.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Dose escalation

Subjects enrolled in this arm will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.

Dose escalation will be carried out according to a modified 3+3 dose-escalation design. Accelerated dose titration design will be used for the first 4 dose levels (0.006mg/kg, 0.06mg/kg, 0.3mg/kg and 1.0mg/kg) and then traditional 3+3 dose escalation design will be used for the following levels (2.0mg/kg, 4.0mg/kg, 8.0mg/kg, 16mg/kg and 24mg/kg).
Drug: CM313-Dose escalation
Subjects will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.
Experimental: Dose expansion _Cohort 1
This cohort will comprise subjects with RRMM. Subjects will receive the CM313 in combination with dexamethasone.
Drug: CM313
Subjects will have 8 infusions at weekly intervals, and then 8 infusions at bi-weekly intervals. After that CM313 will be given every 4 weeks until disease progression or unacceptable toxicity.
Drug: Dexamethasone
dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
Experimental: Dose expansion _Cohort 2
This cohort will comprise subjects with RRMM and NDMM. Subjects will receive the CM313 in combination with Rd regimen.
Drug: CM313
Subjects will have 8 infusions at weekly intervals, and then 8 infusions at bi-weekly intervals. After that CM313 will be given every 4 weeks until disease progression or unacceptable toxicity.
Drug: Dexamethasone
dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
Drug: Lenalidomide
25 mg/day lenalidomide 21 of 28 days cycle

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dose escalation: Number of Participants with a Dose-Limiting Toxicity (DLT)
Time Frame: Up to 21 days after the first dose
Up to 21 days after the first dose
Dose escalation and Dose expansion: Incidence, severity, and outcome of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0
Time Frame: Up to 30 days after the last dose of CM313 or until the start of subsequent anticancer therapy, if earlier
Up to 30 days after the last dose of CM313 or until the start of subsequent anticancer therapy, if earlier
Dose expansion: To evaluate the activity of CM313 in combination with Rd/Dexamethasone as assessed by overall response rate (ORR) in RRMM patients
Time Frame: Up to 24 months
ORR is defined as the proportion of participants who have a partial response (PR) or better according to the international myeloma working group (IMWG) criteria.
Up to 24 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dose escalation: AUC to the last quantifiable concentration [AUC(0-last)], over the dosing interval [AUC(0-tau)], extrapolated to infinity [AUC(0-inf), time to Cmax (tmax), apparent half-life (t1/2), systemic clearance (CL).
Time Frame: 21 days after the first dose
21 days after the first dose
Dose escalation and Dose expansion: AUC(0-last), AUC(0-tau), Cmax, t1/2, systemic clearance (CL), volume of distribution (Vz, Vss), minimum concentration (Cmin), Ctrough, accumulation ratios for Cmax and AUC(0-tau) for multiple doses
Time Frame: up to 24 months
up to 24 months
Dose escalation and Dose expansion: Incidence of anti-CM313
Time Frame: up to 24 months
up to 24 months
Dose escalation: Overall Response Rate (ORR)
Time Frame: up to 24 months
ORR is defined as the proportion of participants who have a partial response (PR) or better according to the IMWG criteria.
up to 24 months
Dose escalation and Dose expansion: Clinical Benefit Rate (CBR)
Time Frame: up to 24 months
CBR is defined as the proportion of participants who have a minimal response (MR) or better according to the IMWG criteria.
up to 24 months
Dose escalation and Dose expansion: Duration of Response (DOR)
Time Frame: From the date of initial documentation of a response to the date of first documented evidence of progressive disease (PD) (up to 24 months)
DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of PD, per IMWG criteria.or better according to the IMWG criteria.
From the date of initial documentation of a response to the date of first documented evidence of progressive disease (PD) (up to 24 months)
Dose escalation and Dose expansion: Time to Response (TTR)
Time Frame: From the date of initial documentation of a response to the date of first documented evidence of progressive disease (PD) (up to 24 months)
TTR is defined as the time between date of first dose of study drug and the first efficacy evaluation that the participant has met all criteria for PR or better.
From the date of initial documentation of a response to the date of first documented evidence of progressive disease (PD) (up to 24 months)
Dose escalation and Dose expansion: Progression-Free Survival (PFS)
Time Frame: up to 24 months
PFS is defined as time from date of first dose of study drug to date of first documented PD, per IMWG criteria, or death due to any cause, whichever occurs first.
up to 24 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Keymed Biosciences Co.Ltd

Investigators

  • Principal Investigator: Wenming Chen, Dr., Beijing Chao Yang Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 26, 2021

Primary Completion (Anticipated)

January 1, 2023

Study Completion (Anticipated)

April 1, 2023

Study Registration Dates

First Submitted

March 24, 2021

First Submitted That Met QC Criteria

March 24, 2021

First Posted (Actual)

March 26, 2021

Study Record Updates

Last Update Posted (Actual)

November 12, 2021

Last Update Submitted That Met QC Criteria

November 11, 2021

Last Verified

November 1, 2021

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CM313MM001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lymphoma

Clinical Trials on CM313-Dose escalation

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe